SOURCE: BioMedReports


March 03, 2011 07:01 ET

Expert Briefing: Radient Pharmaceuticals' Onko-Sure & General Cancer Screening Program in India

LOS ANGELES, CA--(Marketwire - March 3, 2011) - A BioMedReports Expert Briefing has been published by Umesh Bhatia, Ph.D. -- the scientist, entrepreneur and business executive tasked with widespread deployment of Radient Pharmaceuticals' (NYSE Amex: RPC) patented and FDA approved in-vitro diagnostic (IVD) test used in the detection of cancer.

A full special report about the company's cancer screening programs in India is now available at:

Investors interested in accessing BioMedReports' complete database of clinical trials and upcoming FDA decisions can go to:
News developments and live healthcare sector updates are available constantly via twitter at:

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information are available at BioMedReports.Com

Contact Information

  • Media Contacts Only:

    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556